美国处方阿片类药物趋势- IQVIA - 中国竞技竞彩,王者荣耀kpl外围投注,王者荣耀外围竞猜

王者荣耀kpl外围投注
The IQVIA Institute
Reports
美国处方阿片类药物趋势

美国处方阿片类药物趋势

Measuring and understanding progress in the opioid crisis

Institute Report

Dec 16, 2020

Download

About the Report

阿片类药物流行已经吸引了该国十年了，尽管面对COVID-19的大流行，今年失去了关注，这影响了慢性疼痛和成瘾的患者的生活和医疗保健以及许多其他人的生活和医疗保健。lol买外围用什么软件COVID-19对使用处方阿片类药物的影响很小，自6月以来，其使用主要反弹至基线水平。尽管如此，预计2020年的处方阿片类药物使用的两位数下降又有望进一步将美国的使用降低为自2000年代初以来未见的水平。尽管在全国范围内对阿片类药物流行的人类损失却有所不同，但在管理处方阿片类药物和支持药物辅助治疗方面的努力显示出许多州的可衡量进展。

报告摘要

This report provides a timely view of levels of, and trends in, opioid prescribing, how those vary by state, and how those variations illustrate progress and remaining risks. Prescription opioid volume is expected to drop for the ninth consecutive year — a decline of 60% from its peak in 2011. Per capita use of prescription opioids is expected to drop back to levels of use seen in the early 2000, with the greatest reductions in prescription opioid use – as measured in morphine milligram equivalents (MME) – seen in higher-risk segments taking more than 90 MMEs (per day. The greatest declines in prescription opioid use are seen in states which previously had the highest per capita use.

在减少最高风险的处方并与称为苯二氮卓类药物的阿片类药物的共同处方方面取得了进一步的进展，这与较高的过量和死亡风险有关。然而，与年轻患者相比，在65岁以上的患者中，共同处方的阿片类药物和苯二氮卓类药物的使用下降量较小。自2016年以来，阿片类药物和苯二氮卓类药物的总处方下降了30％，但估计接受合并方案的老年人人数仍然很大，为120万老年人。

There are sometimes no other alternatives to opioids for pain management, and current drugs for opioid use disorders are themselves narcotics, driving an intense research effort for alternatives, with only limited progress emerging. Treating underlying diseases with symptomatic pain and developing non-opioid therapies is the focus of the current pipeline. Unmet needs in addiction additionally are being addressed with ongoing research on new mechanisms of action and digital therapeutics.

关键发现

Total national prescription opioid use has declined to 60% of the peak volume in 2011 after another year of double digit decline expected in 2020

Per capita use of prescription opioids is expected to drop back to levels of use seen in the early 2000.
Since 2011, total opioid prescriptions have declined by 40%, with declines of 51% and 63% in commercial and cash pay types.

Trends in use of prescription opioids and medication-assisted treatment quickly returned to pre-pandemic levels after initial disruptions

During the COVID-19 pandemic, as many as 44% fewer patients started new opioid therapy while MAT was less impacted.
Total opioid prescribing declined 16% at the peak of shutdowns in late April, with significant variations across key specialties.
Healthcare providers have prescribed longer opioid prescriptions to mitigate COVID-19 disruptions.
Trends in use of prescription opioids and medication-assisted treatment quickly returned to pre-pandemic levels after initial disruptions.

There is a significant cluster of states with both opioid and MAT use above the national average

Use of medication-assisted treatment, which was disrupted in 2020 due to COVID-19, remains highly variable across states.
2019年，与2018年相比，每个州的阿片类药物MME下降，全国平均水平下降了15％。
The greatest declines in prescription opioid use are seen in states which previously had the highest per capita use.

Co-prescribing benzodiazepines and opioids — consistently identified as increasing the risk of abuse and/or death — has declined in recent years, but still occurs in more than 1 million patients over the age of 65

在65岁以上的患者中，阿片类药物和苯二氮卓治疗的下降量少于年轻患者。
据估计，大约有65岁以上的美国人将接受联合方案，因此有虐待和/或死亡的风险增加。
这个数字从2016年的大约170万下降，比65岁以下的年龄较低。
A total of about 18 million seniors are using prescription opioids, benzodiazepines, or a combination, representing about 30% of the 59.4 million total Americans receiving these medicines.